Sanofi (SNY) Non-Current Assets (2009 - 2026)
Sanofi (SNY) posted Non-Current Assets of $113.4 billion for Q2 2026, down 1.04% sequentially from $114.6 billion in Q1 2026, and up 13.89% YoY from $99.5 billion in Q2 2025.
Sanofi (SNY) Non-Current Assets (2009 - 2026) Analysis & Trends
Sanofi has reported Non-Current Assets for 18 years, with the latest figure at $113.4 billion in Q2 2026.
- Quarterly Non-Current Assets rose 13.89% year-over-year to $113.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $451.5 billion (up 14.09% YoY) and the FY2025 annual result came in at $111.6 billion, up 15.75% from the prior year.
- Non-Current Assets declined to $113.4 billion in Q2 2026 per SNY's latest filing, from $114.6 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $114.6 billion in Q1 2026 and troughed at $92.4 billion in Q1 2025.
- A 5-year average of $104.0 billion and a median of $103.5 billion in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets decreased 7.9% in 2022, then increased 23.95% in 2026.
- Over 5 years, Non-Current Assets stood at $94.5 billion in 2022, then climbed by 9.08% to $103.1 billion in 2023, then declined by 6.47% to $96.4 billion in 2024, then grew by 15.75% to $111.6 billion in 2025, then gained by 1.61% to $113.4 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $113.4 billion, $114.6 billion, and $111.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113.37 Bn |
| Mar 31, 2026 | 114.57 Bn |
| Dec 31, 2025 | 111.58 Bn |
| Sep 30, 2025 | 111.94 Bn |
| Jun 30, 2025 | 99.55 Bn |
| Mar 31, 2025 | 92.43 Bn |
| Dec 31, 2024 | 96.40 Bn |
| Jun 30, 2024 | 107.34 Bn |
| Dec 31, 2023 | 103.07 Bn |
| Jun 30, 2023 | 103.86 Bn |
| Dec 31, 2022 | 94.49 Bn |
| Jun 30, 2022 | 99.73 Bn |
| Dec 31, 2021 | 102.59 Bn |
| Jun 30, 2021 | 99.74 Bn |
| Dec 31, 2020 | 96.23 Bn |
| Jun 30, 2020 | 89.25 Bn |
| Dec 31, 2019 | 667.12 Mn |
| Jun 30, 2019 | 95.77 Bn |
| Dec 31, 2018 | 155.23 Mn |
| Jun 30, 2018 | 106.03 Bn |